Cipher Pharmaceuticals - CPH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: C$8.75
  • Forecasted Upside: 3.18%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$8.48
▲ +0.13 (1.56%)

This chart shows the closing price for CPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cipher Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CPH

Analyst Price Target is C$8.75
▲ +3.18% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cipher Pharmaceuticals in the last 3 months. The average price target is C$8.75, with a high forecast of C$9.50 and a low forecast of C$8.00. The average price target represents a 3.18% upside from the last price of C$8.48.

This chart shows the closing price for CPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in Cipher Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/13/2024Stifel NicolausDowngradeBuy ➝ HoldC$8.00 ➝ C$9.50
2/14/2024CitigroupBoost TargetSpeculative Buy ➝ BuyC$4.75 ➝ C$8.00
3/17/2023Leede Jones GabReiterated RatingBuy
5/13/2022Echelon Wealth PartnersReiterated RatingBuy
3/22/2021Leede Jones GabUpgradeSpeculative Buy ➝ Buy
5/8/2020Bloom BurtonUpgradeHold ➝ Accumulate
8/14/2019TD SecuritiesLower TargetHoldC$2.00 ➝ C$1.50
8/12/2019Bloom BurtonReiterated RatingHold
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cipher Pharmaceuticals logo
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: C$8.48
Low: C$8.23
High: C$8.50

50 Day Range

MA: C$8.76
Low: C$8.31
High: C$9.32

52 Week Range

Now: C$8.48
Low: C$3.30
High: C$10.33

Volume

88,707 shs

Average Volume

34,326 shs

Market Capitalization

C$204.45 million

P/E Ratio

6.89

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Cipher Pharmaceuticals?

The following sell-side analysts have issued research reports on Cipher Pharmaceuticals in the last twelve months: Citigroup Inc., and Stifel Nicolaus.
View the latest analyst ratings for CPH.

What is the current price target for Cipher Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Cipher Pharmaceuticals in the last year. Their average twelve-month price target is C$8.75, suggesting a possible upside of 3.2%. Stifel Nicolaus has the highest price target set, predicting CPH will reach C$9.50 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of C$8.00 for Cipher Pharmaceuticals in the next year.
View the latest price targets for CPH.

What is the current consensus analyst rating for Cipher Pharmaceuticals?

Cipher Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CPH.

What other companies compete with Cipher Pharmaceuticals?

How do I contact Cipher Pharmaceuticals' investor relations team?

Cipher Pharmaceuticals' physical mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company's listed phone number is +1-905-6025840. The official website for Cipher Pharmaceuticals is www.cipherpharma.com. Learn More about contacing Cipher Pharmaceuticals investor relations.